Novo Nordisk Shares Plummet to Four-Year Low After Alzheimer’s Trial Failure and Weight-Loss Drug War
Novo Nordisk shares hit a four-year low after its Alzheimer's trial failed, compounding pressure from Eli Lilly's Zepbound and steep Wegovy price cuts. The Danish pharma giant's market value has plunged over 50% in 2025.
Continue reading...